The Latest Updates from ReSPECT Clinical Trials
Advancing Treatment for Pediatric Brain Cancer
ReSPECT-PBC Clinical Trial: Advancing Treatment for Pediatric Brain Cancer Pediatric brain tumors are among the leading causes of cancer-related deaths in children, with limited treatment options for aggressive tumors like ependymoma and high-grade glioma (HGG). The...
Introducing REYOBIQ™
Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...
Advancing Treatment for Leptomeningeal Metastases
Advancing Treatment for Leptomeningeal Metastases (LM): ReSPECT-LM Clinical Trial Now Enrolling Leptomeningeal metastases (LM) is a devastating complication of cancer, occurring when malignant cells spread to the cerebrospinal fluid (CSF) and leptomeninges, leading to...
Nature Publication
Phase 1 Clinical Trial Results for Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma (GBM) Now in Nature Communications 📢 Exciting News! The results of our Phase 1 clinical trial for Rhenium (186Re) Obisbemeda in recurrent glioblastoma (GBM) have been published in...
LM ODD for Lung Cancer Patients
FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Lung Cancer Patients with Leptomeningeal Metastases We are thrilled to announce that the U.S. FDA has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of...
Advancing Treatment for Recurrent Glioblastoma
ReSPECT-GBM Clinical Trial: Advancing Treatment for Recurrent Glioblastoma (GBM) Glioblastoma (GBM) is one of the most aggressive and treatment-resistant brain cancers, with limited therapeutic options available for patients with recurrent disease. The ReSPECT-GBM...
#RareDiseaseDay2025
Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...
ReSPECT-LM Phase 1 Single Dose Completed
BREAKING NEWS: ReSPECT-LM Phase 1 Single Dose Completed – Phase 2 Dose Determined We are thrilled to announce a major milestone in the ReSPECT-LM clinical trial! The Phase 1 single-dose portion of the trial is now complete, and the recommended Phase 2 dose (RP2D) for...
CNSide Diagnostics Leadership Appointments
Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...
Welcome Michael Rosol, PhD!
Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...
$5.7 Million PSTV Funding
Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...
February is Patient Appreciation Month!
Celebrating Strength and Resilience: Patient Appreciation Month At Plus Therapeutics, we are honored to celebrate #PatientAppreciationMonth and recognize the incredible strength, resilience, and courage of patients facing cancer. 🧡 Every day, we are inspired by those...
OSU: New ReSPECT-GBM Site
New Clinical Trial Site Now Enrolling – OSUCCC-James Joins ReSPECT-GBM! We are excited to announce that The Ohio State University Comprehensive Cancer Center – James (OSUCCC – James) has joined our ReSPECT-GBM Clinical Trial as a new investigation site, with Principal...
#WorldCancerDay2025
Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...
YouTube Channel
Catch Up on Our Latest Videos – Now on YouTube! Did you miss any of our recent videos? Don't worry—they're all available on our Plus Therapeutics YouTube channel! 🔹 Stay informed with expert discussions on cutting-edge cancer research. 🔹 Hear from patients sharing...
Thank You to Our Patients!
A Heartfelt Thank You to Our ReSPECT-GBM & ReSPECT-LM Clinical Trial Participants To every patient who has participated in the ReSPECT-GBM and ReSPECT-LM clinical trials: THANK YOU! 💙 Your courage and commitment are helping advance critical research for recurrent...
Comprehensive Patient Guides
Comprehensive Patient Guides for Rare Diseases Are you looking for reliable, in-depth information on rare cancers and brain tumors? Our patient guides provide essential insights tailored for cancer patients and caregivers. Each guide covers: ✅ Disease background –...
ResPECT-LM on MBCBrainMets.org
ReSPECT-LM Clinical Trial: Now Featured on MBCBrainMets.org! 📢 Exciting news! The ReSPECT-LM Clinical Trial is now a featured clinical trial on MBCBrainMets.org, a trusted resource hub for breast cancer patients living with brain metastases. 🔎 Learn more about the...
Follow @PlusTherapeutics!
Stay Updated with Plus Therapeutics – Follow Us & Subscribe! Want the latest updates on Plus Therapeutics and cutting-edge industry news? Stay informed by following us on all our social media accounts and subscribing to our email newsletter! 🔹 Be the first to know...
ReSPECT-GBM Closes Phase 1
ReSPECT-GBM Clinical Trial Update: Phase 2 Enrollment Now Open We are excited to announce that enrollment for the Phase 1 ReSPECT-GBM clinical trial is complete! We are actively enrolling patients for Phase 2 of the trial, which focuses on treating recurrent...
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 Advancing Treatment for Pediatric Brain Cancer
- 1.2 Introducing REYOBIQ™
- 1.3 Advancing Treatment for Leptomeningeal Metastases
- 1.4 Nature Publication
- 1.5 LM ODD for Lung Cancer Patients
- 1.6 Advancing Treatment for Recurrent Glioblastoma
- 1.7 #RareDiseaseDay2025
- 1.8 ReSPECT-LM Phase 1 Single Dose Completed
- 1.9 CNSide Diagnostics Leadership Appointments
- 1.10 Welcome Michael Rosol, PhD!
- 1.11 $5.7 Million PSTV Funding
- 1.12 February is Patient Appreciation Month!
- 1.13 OSU: New ReSPECT-GBM Site
- 1.14 #WorldCancerDay2025
- 1.15 YouTube Channel
- 1.16 Thank You to Our Patients!
- 1.17 Comprehensive Patient Guides
- 1.18 ResPECT-LM on MBCBrainMets.org
- 1.19 Follow @PlusTherapeutics!
- 1.20 ReSPECT-GBM Closes Phase 1